Novel hormone treatment of benign metastasizing leiomyoma: an analysis of five cases and literature review  Erin I. Lewis, M.D., Rebecca J. Chason, M.D., Alan H. DeCherney, M.D., Alicia Armstrong, M.D., John Elkas, M.D., Aradhana M. Venkatesan, M.D.  Fertility and Sterility  Volume 99, Issue 7, Pages 2017-2024 (June 2013) DOI: 10.1016/j.fertnstert.2013.01.147 Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 1 ER/PR receptor status of BML case reports, 1986–2012. Fertility and Sterility 2013 99, 2017-2024DOI: (10.1016/j.fertnstert.2013.01.147) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Tumor burden measured by RECIST 1.1 (19). (A1) Axial contrast-enhanced CT of the pelvis for case 1 pretreatment, March 2008. (A2) Axial contrast enhanced CT of the pelvis for case 1 post-treatment, January 2010—stable disease (9.2% decrease). (B1) Axial T2 weighted MRI of the pelvis for case 2 pretreatment, October 2008. (B2) Axial T2 weighted MRI of the pelvis for case 2 post-treatment, February 2008—stable disease (22.0% decrease). (C1) Axial fat suppressed contrast-enhanced MRI of the pelvis for case 3 pretreatment, February 2009. (C2) Axial fat suppressed contrast-enhanced MRI of the pelvis for case 3 post-treatment, August 2009—stable disease (20.4% decrease). (D1) Axial contrast–enhanced CT of the pelvis for case 4 pretreatment, November 2007. (D2) Axial contrast-enhanced CT of the pelvis for case 4 post-treatment, February 2008—stable disease (3.6% decrease). (E1) Axial T2 weighted MRI of the pelvis for case 5 pretreatment, June 2007. (E2) Axial T2 weighted MRI of the pelvis for case 5 post-treatment, September 2011—progressive disease (44.3% progression). Fertility and Sterility 2013 99, 2017-2024DOI: (10.1016/j.fertnstert.2013.01.147) Copyright © 2013 American Society for Reproductive Medicine Terms and Conditions